Part 11 Compliance Is Not a Vendor Feature

Part 11 compliance is an organizational commitment, not a software feature.

In regulated organizations, one statement should immediately trigger additional questions:

“The vendor says the system is Part 11 compliant.”

That statement may describe the software’s technical capabilities. It may mean the system includes electronic signatures, configurable audit trails, security roles, time stamps, record-retention functions, or other features associated with 21 CFR Part 11.

It does not establish that the organization using the system is compliant.

A vendor can provide technology designed to support compliance. The regulated company must determine whether Part 11 applies, define how the system will be used, configure the appropriate controls, validate the intended use, govern user access, maintain procedures, train personnel, review records, manage changes, and preserve evidence throughout the system lifecycle.

Those responsibilities do not transfer to the vendor when the software is purchased.

21 CFR Part 11 establishes the criteria under which FDA considers electronic records and electronic signatures to be trustworthy, reliable, and generally equivalent to paper records and handwritten signatures.

The regulation applies when electronic records are created, modified, maintained, archived, retrieved, or transmitted under FDA recordkeeping requirements. It also applies to certain electronic records submitted to FDA.

That means the starting point is not the software package.

The starting point is the regulated record.

Organizations need to understand:

Which electronic records are required by an applicable predicate rule
Whether the electronic record or a paper record is relied upon to perform the regulated activity
Which electronic signatures are intended to serve as legally binding equivalents of handwritten signatures
How the system affects product quality, patient safety, data integrity, and regulatory decisions
Which controls are necessary based on the system’s intended use and risk

FDA’s Part 11 Scope and Application guidance recommends that organizations determine which records are Part 11 records and document those decisions. FDA also notes that actual business practices may influence whether the electronic record is considered the record relied upon for regulated activity.

A vendor cannot make that determination for the organization. The vendor does not own the predicate-rule analysis, the regulated process, or the decision about which record serves as the official record.

“The vendor validated it” is not a validation strategy

Vendor testing can be useful. In many cases, it is an important part of supplier evaluation and the overall validation package.

A capable vendor may provide:

Software-development and testing documentation

Functional and design specifications

Release notes

Traceability information

Security documentation

Standard test scripts

Audit-trail specifications

Configuration guidance

Known-error or defect information

Evidence supporting infrastructure qualification

That evidence can reduce unnecessary duplication when it is appropriately evaluated. It does not eliminate the regulated company’s responsibility to demonstrate that the configured system is fit for its intended use in the company’s process and operating environment.

The organization still needs to define what the system is expected to do, which functions are critical, how risks will be controlled, what testing is necessary, and how the evidence supports the intended use.

A vendor may have tested an audit-trail function. That does not demonstrate that your organization enabled the audit trail, protected it from inappropriate modification, assigned responsibility for reviewing it, or established criteria for investigating unusual activity.

The vendor may have tested role-based access. That does not demonstrate that your user roles are appropriately designed, approved, periodically reviewed, and removed when personnel change positions or leave the organization.

The vendor may have tested an electronic-signature workflow. That does not show that the meaning of each signature is clear, that signatures remain linked to their records, or that personnel understand the legal and procedural significance of using them.

Validation is not simply evidence that the software works.

It is documented evidence that the system, as implemented and used by the organization, consistently performs its intended regulated functions.

Access control must establish individual accountability

Access control is often treated as an information-technology issue. Under Part 11 and the applicable predicate rules, it is also a records-accountability issue.

Section 11.10 requires closed systems to include controls that limit access to authorized individuals. It also requires authority checks designed to ensure that only authorized individuals can use the system, electronically sign a record, alter a record, or perform a particular operation.

For pharmaceutical manufacturing, 21 CFR 211.68 requires appropriate controls over computer systems to ensure that changes to master production and control records or other records are instituted only by authorized personnel. eCFR

A login screen by itself does not demonstrate control.

The organization should be able to explain and provide evidence for:

How user access is requested, approved, created, modified, and removed
Why each role has its assigned privileges
How access aligns with job responsibilities
How privileged and administrator access is restricted
Whether individuals performing regulated work can delete or alter underlying records
How segregation of duties is maintained
How shared or generic accounts are prevented or tightly controlled
How periodic access reviews are performed
How access changes are documented
How contractors, temporary personnel, and vendor support accounts are governed

These are not theoretical concerns.

Recent FDA enforcement actions have continued to identify weaknesses involving shared credentials, excessive administrator privileges, inadequate audit-trail controls, and the ability to modify or delete regulated data without appropriate oversight. These findings reinforce a broader point: the existence of technical functionality does not compensate for weak governance over how a system is configured, accessed, reviewed, and maintained.

The regulatory concern is not limited to whether a system includes security features. The organization must be able to demonstrate that access is appropriately restricted, administrator privileges are justified, electronic records are protected, audit trails are meaningful, and management oversight is effective.

An audit trail is not effective simply because it exists

Many systems are marketed as Part 11 capable because they include an audit-trail function.

The more relevant questions are:

Is the audit trail enabled for the appropriate records and activities?
Can ordinary users disable or modify it?
Does it capture the creation, modification, and deletion of regulated records?
Does the entry identify who performed the action and when?
Is the reason for a change captured when required?
Does the audit trail preserve the original information?
Can reviewers understand the sequence of events?
Is audit-trail review incorporated into the applicable record-review process?
Are unusual events escalated and investigated?
Is evidence of the review retained?

Section 11.10(e) describes secure, computer-generated, time-stamped audit trails that independently record actions creating, modifying, or deleting electronic records. It also states that changes must not obscure information that was previously recorded. eCFR

FDA’s Part 11 guidance discusses enforcement discretion for certain audit-trail requirements. That should not be interpreted to mean audit trails are optional whenever electronic regulated records are involved. The same guidance states that audit trails or other security measures may be important to ensure record trustworthiness and reliability and recommends that decisions be based on predicate-rule requirements, documented risk assessment, product quality, safety, and record integrity. U.S. Food and Drug Administration

The FDA Data Integrity and Compliance With Drug CGMP guidance reinforces the expectation that data supporting CGMP activities be reliable and accurate and that firms implement meaningful, risk-based strategies to prevent and detect data-integrity problems. U.S. Food and Drug Administration

An audit trail that is never reviewed may preserve information, but it does not provide effective oversight.

An audit trail that can be disabled without detection may create the appearance of control without providing reliable evidence.

An audit trail review performed only after an inspection is announced does not demonstrate routine governance.

The organization must decide what will be reviewed, who will perform the review, when it will occur, what constitutes an exception, and how exceptions will be documented and investigated.

FDA’s enforcement discretion is not a general exemption

Part 11 discussions frequently become confused when FDA’s enforcement-discretion policy is raised.

FDA’s Scope and Application guidance explains that the agency interprets Part 11 narrowly and exercises enforcement discretion for certain requirements under the circumstances described in the guidance. At the same time, FDA expressly states that Part 11 remains in effect, that predicate-rule requirements continue to apply, and that it intends to enforce other Part 11 provisions, including controls involving authorized access, operational checks, authority checks, systems documentation, accountability for electronic signatures, and electronic-signature requirements. U.S. Food and Drug Administration

Organizations therefore need more than a general statement that FDA exercises enforcement discretion.

They need a documented position addressing:

Which records and signatures are in scope
Which predicate rules apply
How the organization relies on the electronic record
Which controls are necessary to maintain trustworthy and reliable records
How risks to product quality, patient safety, and record integrity are managed
What evidence demonstrates that the controls are operating effectively

A vendor’s general interpretation cannot replace an organization-specific regulatory assessment.

Compliance has to survive the system lifecycle

The initial implementation receives significant attention in most organizations. The larger risk often develops after go-live.

Over time:

User roles change
Personnel transfer or leave
New interfaces are added
Vendors release software updates
Infrastructure is migrated
Configurations are modified
Workarounds develop
Business processes expand
Data volumes increase
Review activities become routine and may lose effectiveness
Knowledge becomes concentrated in a few experienced individuals

A system that was appropriately validated five years ago may no longer be operating under the same configuration, process, infrastructure, or risk profile.

Sustainable Part 11 compliance therefore requires lifecycle governance, including:

Defined system ownership
Quality-unit oversight
Periodic review
Access recertification
Change control
Configuration management
Incident and deviation management
Backup and restoration testing
Business-continuity planning
Vendor-performance monitoring
Assessment of upgrades and patches
Data migration controls
Record retention and retrieval
Controlled system retirement and data archiving

The software remains a technical asset. The compliance posture is created by the operating model surrounding it.

What should the system owner be able to defend?

A system owner should be able to answer more than whether the software has Part 11 features.

At a minimum, the owner and supporting functions should be able to explain:

Which regulated records and signatures are managed by the system?

Which predicate rules establish the recordkeeping requirements?

What is the approved intended use of the system?

Which functions are critical to product quality, patient safety, and data integrity?

How was vendor documentation evaluated and incorporated into the validation approach?

What testing was performed for the organization’s configuration and business process?

How are roles, privileges, and administrator access governed?

Which audit trails are enabled, and how are they reviewed?

How are electronic signatures controlled and linked to their records?

How are changes, upgrades, incidents, backups, and periodic reviews managed?

Can accurate and complete records be produced in a form suitable for FDA inspection and review?

What evidence demonstrates that these controls continue to operate effectively?

If the answer to most of these questions is “the vendor handles it,” the organization may have purchased useful software without establishing an adequate compliance framework.

The distinction that matters under FDA scrutiny

A vendor may legitimately state that its product includes capabilities designed to support 21 CFR Part 11 requirements.

That is not the same as demonstrating that a regulated organization has implemented, validated, and governed the system appropriately.

Under inspection, the organization must be prepared to show how the system is actually used. That includes the records it manages, the people who can access it, the privileges they hold, the changes they can make, the audit evidence available, the procedures governing the system, and the management oversight used to maintain control.

The most important question is not:

“Does the software have Part 11 functionality?”

It is:

“Can the organization demonstrate that its electronic records and signatures remain trustworthy, reliable, complete, secure, and available throughout their lifecycle?”

That responsibility belongs to the regulated organization.

Assess your Part 11 readiness

Bayou Vantage helps Life Sciences organizations evaluate the gap between technical system capability and sustainable regulatory compliance.

A Bayou Vantage Part 11 Readiness Assessment can examine:

Part 11 applicability and predicate-rule analysis

Electronic-record and signature inventories

System-owner and Quality-unit accountability

Intended-use and validation documentation

Vendor qualification and supplier oversight

User-access and privileged-access controls

Audit-trail configuration and review

Electronic-signature controls

Data retention, backup, restoration, and retrieval

Change control and periodic review

Inspection evidence and system documentation

Lifecycle and decommissioning governance

The objective is not to determine whether a vendor checked the appropriate boxes.

It is to determine whether your organization can defend how the system is governed, how the records are protected, and how the controls operate when FDA asks to see the evidence.

Contact Bayou Vantage to schedule a Part 11 Readiness Assessment and identify where your computerized-system controls are defensible, where they rely too heavily on vendor claims, and what should be strengthened before the next inspection.

[Start a conversation]/(contact)